Benefits
High-Purity, Bioavailable Form
pTeroWhite® delivers ~99% trans-pterostilbene, the methylated resveratrol analog whose two methoxy groups improve lipophilicity, slow first-pass metabolism, and extend half-life. This supports more reliable plasma exposure than equivalent resveratrol, making it a practical antioxidant building block.
Antioxidant Pathway Activity (Preclinical)
In cell and animal models pterostilbene activates the Nrf2 pathway that governs the body's own antioxidant enzymes. That is a laboratory rationale, not a demonstrated human effect: in a two-month randomized, double-blind, placebo-controlled trial of an oral 90%-pterostilbene extract in 60 healthy adults, serum antioxidant enzyme levels did not differ significantly from placebo.
Metabolic and Cardiovascular Support
In a single randomized, placebo-controlled trial in 80 adults with elevated cholesterol, pterostilbene at 250 mg/day lowered systolic blood pressure by 7.8 mmHg and diastolic by 7.3 mmHg. In that same trial LDL cholesterol rose by 17.1 mg/dL when pterostilbene was taken on its own - the authors made that increase part of their conclusion. The rise was not seen when pterostilbene was paired with grape extract, and it appeared blunted in people already on a cholesterol medication. Pterostilbene is not a lipid-lowering agent, and anyone tracking LDL should have it rechecked.
Longevity Interest Remains Preclinical
Preclinical work links pterostilbene to SIRT1 signaling, neuroprotection and aging pathways, and it is a common component of NAD+/sirtuin stacks. That work is entirely cells, rodents and fruit flies. No published trial has measured cognition, healthspan or a validated aging biomarker in people taking pterostilbene on its own, and the human NAD+ studies commonly cited for it tested pterostilbene combined with nicotinamide riboside, with no pterostilbene-only arm, so the NAD+ increase in those trials cannot be attributed to pterostilbene.
Anti-Inflammatory Profile
Pterostilbene modulates NF-κB-driven inflammatory signaling in laboratory models. When that was tested in people it did not carry over: oral dosing of 450 mg of a pterostilbene-standardized Pterocarpus marsupium extract in healthy volunteers raised serum pterostilbene but did not reduce ex vivo PGE2 production, and the blood levels reached were about five-fold below the concentration active in the cell assay.
Mechanism of action
Improved Pharmacokinetics vs Resveratrol
Two methoxy groups (replacing resveratrol's hydroxyls) make pterostilbene more lipophilic, improving membrane penetration and resistance to first-pass metabolism. The result is higher oral bioavailability and a longer plasma half-life for the same stilbene core, a difference established mainly in rodent pharmacokinetic work rather than by head-to-head human comparison.
Nrf2 Antioxidant Pathway Activation
In cell and animal models pterostilbene activates the Nrf2 transcription factor, upregulating endogenous antioxidant enzymes such as superoxide dismutase, catalase and glutathione-synthesizing enzymes. Whether this happens in people who take it is unresolved: serum antioxidant enzyme levels did not change significantly versus placebo in a two-month randomized trial in 60 healthy adults.
SIRT1 Signaling
Like resveratrol, pterostilbene engages SIRT1 deacetylase signaling implicated in mitochondrial biogenesis and glucose handling. Better bioavailability is the proposed advantage, though clinical confirmation of longevity outcomes is lacking.
PPAR-alpha and Lipid Metabolism
Pterostilbene modulates PPAR-alpha, a nuclear receptor governing fatty-acid oxidation and lipid handling, which may underlie its metabolic effects observed in animal models.
Clinical trials
Randomized, double-blind, placebo-controlled trial in 80 adults with elevated cholesterol over 6–8 weeks, with four arms: pterostilbene 125 mg twice daily; pterostilbene 50 mg twice daily; pterostilbene 50 mg plus grape extract 100 mg twice daily; or matching placebo (ClinicalTrials.gov NCT01267227). The material tested was pTeroPure®, a >99% all-trans-pterostilbene supplied by ChromaDex, Inc., which also funded the trial. It was not pTeroWhite®.
80 adults with hypercholesterolemia.
The authors' stated conclusion was that pterostilbene increases LDL and reduces blood pressure. LDL rose by 17.1 mg/dL with pterostilbene monotherapy (P = 0.001); the rise was not seen with the grape-extract combination, and being on a cholesterol medication appeared to attenuate it. The 250 mg/day arm showed reductions in systolic (-7.8 mmHg, P < 0.01) and diastolic (-7.3 mmHg, P < 0.001) blood pressure, and participants not on a cholesterol medication (n = 51) showed a small BMI decrease (-0.62 kg/m2, P = 0.012). With roughly 20 people per arm this is a small trial, and no independent group has replicated it.
The safety report of the identical 80-person trial described above (NCT01267227) - the same participants, the same four arms, the same 6–8 weeks, the same ChromaDex-supplied pTeroPure® material, published separately a year earlier. It evaluated hepatic, renal and glucose markers plus self-reported adverse effects at doses up to 250 mg/day.
80 adults; up to 250 mg/day for 6–8 weeks.
91.3% of participants completed; average age 54, 71% female, 70% Caucasian. There were no adverse drug reactions on hepatic, renal or glucose markers and no statistically significant self-reported or major adverse reactions, supporting short-term tolerability up to 250 mg/day. Follow-up was only 6–8 weeks, so nothing here speaks to longer use - and the LDL increase reported from these same participants is not captured by this panel of safety markers.